Phosphagenics’ business is centred on the commercialisation of the patented pharmaceutical and nutraceutical applications of its research and development (R&D).

Phosphagenics prioritises its development and commercialisation activities, placing emphasis on:

• Development of products with significant global market size potential;
  
  
• Development of differentiated products with a clear competitive advantage in their market segment. For example, products that:
  • Have superior efficacy or convenience; or
  • Satisfy unmet market opportunities or needs.
    
    
• Initiatives with multiple applications, such as:
  • Platform delivery technologies in the Pharmaceutical division; and
  • Products such as Phospha E® with relevance in multiple market segments in the Nutraceutical division.

The route to market for Phosphagenics’ products is through partnering at the appropriate stage in a product’s development, so as to maximise return on the Company’s R&D investment. Phosphagenics does not intend to be a direct marketer of products to consumers. Phosphagenics will however aim to manufacture and supply the active ingredients to its partners or distributors where commercially feasible.

In order to attract marketing and development partners, Phosphagenics conducts proof of concept studies in the laboratory, and in the clinic, to demonstrate the properties and viability of its products.

To maximise long-term shareholder returns, Phosphagenics is progressing towards a self-funding model. Cash generated from the ‘faster to market’ nutraceutical business, will assist in funding attractive pharmaceutical opportunities to a stage where a rewarding partnership/license agreement can be negotiated.